At SDCA Pharmaceuticals, we are dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. Our 2026 pipeline focuses on targeted oncology and precision immunology.
June 14, 2026
The randomized, double-blind study met its primary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful improvement compared to standard of care.
May 28, 2026
This designation is based on the robust efficacy data observed in the Phase 2b clinical cohort for patients with refractory systemic lupus erythematosus.
May 10, 2026
Executive leadership will provide an overview of the company's Q2 performance and an update on the mid-stage clinical pipeline.
Access for SDCA corporate staff, researchers, and facility management. mTLS SmartCard required.
Secure data upload and EDC (Electronic Data Capture) for registered investigators.